Another factor emerging from literature is the increased tendency to BM in CRC with BRAFV600E mutation [7]: the aggressiveness of this CRC subtype is well known, but conclusive data about BM can hardly be drawn due to the rarity of both BRAF-mutated metastatic CRC (mCRC) (8–12% of the total mCRC) [8] and BM. This evidence concerns the gene BRAF and colorectal carcinoma.